CD103+/PD-1+T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition

被引：0
|
作者：
Bottai, G.
Loi, S.
Sotiriou, C.
Roncalli, M.
Pusztai, L.
Reis-Filho, J. S.
Santarpia, L.
机构：
[1] Humanitas Clin & Res Ctr, Milan, Italy
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Inst Jules Bordet, Brussels, Belgium
[4] Humanitas Univ, Milan, Italy
[5] Yale Canc Ctr, New Haven, CT USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-04-16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-04-16
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CD103+/PD-1+T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition
    Bottai, Giulia
    Roncalli, Massimo
    Santarpia, Libero
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [2] Effects of Cardamonin on PD-1/PD-L1 Checkpoint in Triple-Negative Breast Cancer
    Mendonca, Patricia
    Hill, Lonnie
    Soliman, Karam F. A.
    FASEB JOURNAL, 2022, 36
  • [3] Immune checkpoint inhibition in early-stage triple-negative breast cancer
    Varma, Revati
    Wright, Matthew
    Abraham, Jame
    Kruse, Megan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1225 - 1238
  • [4] HDAC inhibition modulates immune checkpoint pathway in triple-negative breast cancer
    Barberio, Manuela Terranova
    Thomas, Scott
    Ali, Niwa
    Pawlowska, Nela
    Park, Jeenah
    Rosenblum, Michael D.
    Budillon, Alfredo
    Munster, Pamela N.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [5] Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
    Camorani, Simona
    Passariello, Margherita
    Agnello, Lisa
    Esposito, Silvia
    Collina, Francesca
    Cantile, Monica
    Di Bonito, Maurizio
    Ulasov, Ilya V.
    Fedele, Monica
    Zannetti, Antonella
    De Lorenzo, Claudia
    Cerchia, Laura
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [6] Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
    Simona Camorani
    Margherita Passariello
    Lisa Agnello
    Silvia Esposito
    Francesca Collina
    Monica Cantile
    Maurizio Di Bonito
    Ilya V. Ulasov
    Monica Fedele
    Antonella Zannetti
    Claudia De Lorenzo
    Laura Cerchia
    Journal of Experimental & Clinical Cancer Research, 39
  • [7] Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Hongshu Li
    Ying Chang
    Tiefeng Jin
    Meihua Zhang
    Cancer Cell International, 25 (1)
  • [8] Reverse engineering of triple-negative breast cancer cells for targeted treatment
    Bluemel, Lena
    von Wahlde, Marie-Kristin
    Tio, Joke
    Kiesel, Ludwig
    Bernemann, Christof
    MATURITAS, 2018, 108 : 24 - 30
  • [9] CD44 Targeted Nanomaterials for Treatment of Triple-Negative Breast Cancer
    Nabil, Ghazal
    Alzhrani, Rami
    Alsaab, Hashem O.
    Atef, Mohammed
    Sau, Samaresh
    Iyer, Arun K.
    El Banna, Hossny
    CANCERS, 2021, 13 (04) : 1 - 27
  • [10] HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts.
    Capasso, Anna
    Lang, Julie
    Pitts, Todd M.
    Francoeur, Paul
    Davis, Sarah Lindsey
    Lieu, Christopher Hanyoung
    Bagby, Stacey M.
    Tentler, John J.
    Piscopio, Anthony D.
    Diamond, Jennifer Robinson
    Pelanda, Roberta
    Eckhardt, S. Gail
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345